Drug intelligence / Profile preview

priscabtagene autoleucel

Development stage: Phase 2
Lead developer: Chongqing Precision Biotech Co., Ltd
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous Infusion

Overview

Priscabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Developed by Chongqing Precision Biotech Co., Ltd, it is designed to target CD19-positive cells, primarily for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The therapy involves genetically modifying a patient's own T-cells to express a CAR that recognizes and binds to the CD19 antigen found on the surface of malignant B-cells, leading to their destruction.

Other names: autologous anti-CD19 CAR vector-transduced T cells pCAR-19BAnti-CD19-Car T cell therapyAnti-CD-19-Car T cell therapyAnti-CD 19-Car T cell therapypCAR-19B细胞自体回输制剂

Targets

CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on priscabtagene autoleucel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on priscabtagene autoleucel.

Explore the full profile